Nestle Health Science is investing $41 million private equity into biopharmaceutical company Enterome to research and develop drugs treating inflammatory bowel disease and food allergies.
Enterome said it plans to use the funding to further develop EB1010, its leading pipeline candidate drug in IBD and food allergies treatment, expected to begin clinical trials next year. Enterome also plans to create allergen immunotherapy, with a particular focus on peanut allergies, designed to suppress allergic reactions, according to a July 18 company news release.
"Approximately 220 million people around the world live with food allergies, while 7 million people live with inflammatory bowel disease," said Hans-Juergen Woerle, chief scientific and medical officer of Nestle Health Science. "Through this collaboration, we are aiming to develop novel therapies for those two disease areas with high unmet medical need."